Optimi Health announces entering into a supply agreement with Halucenex Life Sciences Inc that "pertains to the entirety of" Optimi's recently cultivated psilocybe mushrooms.
Optimi Health announces entering into a supply agreement with Halucenex Life Sciences Inc that "pertains to the entirety of" Optimi's recently cultivated psilocybe mushrooms.
Awakn Life Sciences announces filing a patent application for the treatment of behavioral addictions with ketamine-assisted psychotherapy.
Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.
Optimi Health announces the completion of its first crop of psilocybin mushrooms at the company's Princeton, B.C. cultivation facility.
Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.
The psychedelic drug industry has suddenly attracted the attention of the most influential "power players" on the planet. It's great news for the industry, but...
MindMed announces the appointment of Schond L. Greenway as its new CFO, bringing a wealth of experience in banking and corporate finance.
Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.
GH Research reports its Q1 2022 results. Net loss of $5.8 million. Cash position of $270.8 million as of March 31, 2022.
Seelos Therapeutics announces receiving its Notice of Allowance from the USPTO for SLS-007 as a method of treatment.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now